Avalo Therapeutics Reports Director/Officer Changes & More
Ticker: AVTX · Form: 8-K · Filed: Oct 1, 2025 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Oct 1, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $2.6 billion, $40 billion, $465,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance, filing
Related Tickers: AVTX
TL;DR
AVTX board shakeup, new execs appointed, and comp details filed.
AI Summary
Avalo Therapeutics, Inc. filed an 8-K on October 1, 2025, reporting on events as of September 29, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also includes other events and financial statements/exhibits.
Why It Matters
Changes in a company's board and executive team, along with compensation details, can signal shifts in strategy or financial health.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially if numerous or involving key roles, can indicate internal instability or strategic pivots that carry inherent risks.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- Cerecor Inc. (company) — Former Company Name
- September 29, 2025 (date) — Date of earliest event reported
- October 1, 2025 (date) — Date of Report
FAQ
What specific roles did the departing directors or officers hold?
The filing indicates the departure of directors or certain officers but does not specify their roles in the provided text.
Who are the newly elected directors or appointed officers?
The filing states that directors were elected and officers were appointed, but their names are not detailed in this section of the report.
What are the details of the compensatory arrangements for the officers?
The filing mentions compensatory arrangements of certain officers, but the specific details are not provided in the excerpt.
Are there any significant 'Other Events' being reported?
The filing lists 'Other Events' as an item information category, but the nature of these events is not described in the provided text.
What financial statements or exhibits are included with this filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific contents are not listed in this excerpt.
Filing Stats: 1,210 words · 5 min read · ~4 pages · Grade level 11.3 · Accepted 2025-10-01 07:01:23
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market
- $2.6 billion — ies that ultimately culminated with its $2.6 billion acquisition by Lundbeck. Prior to Longb
- $40 billion — tal Markets where he executed more than $40 billion in mergers and acquisitions and debt an
- $465,000 — vide Mr. Boyd with (i) a base salary of $465,000 and (ii) a discretionary annual bonus w
Filing Documents
- avtx-20250929.htm (8-K) — 34KB
- ex-101employmentagreementx.htm (EX-10.1) — 87KB
- ex-991cboappointmentinduce.htm (EX-99.1) — 17KB
- avalologoa.jpg (GRAPHIC) — 8KB
- 0001534120-25-000009.txt ( ) — 314KB
- avtx-20250929.xsd (EX-101.SCH) — 2KB
- avtx-20250929_def.xml (EX-101.DEF) — 14KB
- avtx-20250929_lab.xml (EX-101.LAB) — 24KB
- avtx-20250929_pre.xml (EX-101.PRE) — 15KB
- avtx-20250929_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 1, 2025, the Company issued a press release announcing the appointment of Taylor Boyd as Chief Business Officer, effective October 1, 2025. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 10.1+ Employment Agreement, dated September 2 9 , 2025, by and between Avalo Therapeutics, Inc. and Taylor Boyd. 99.1 Press Release , dated Octobe r 1 , 2025. 104 The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL. + Management contract or compensation plan or arrangement. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: October 1, 2025 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 3